#MedNews - Sofosbuvir–daclatasvir is noninferior to sofosbuvir–velpatasvir for the treatment of chronic #HCV infection in adults with mild-to-moderate fibrosis.
Full story 👉 buff.ly/f3Bs2wQ
#Hepatitis #IDSky #Sofosbuvir #Daclatasvir
As a reminder ALLY-3+ study longest arm was 16 wks and showed 89% SVR12 with 12 wks #sofosbuvir #daclatasvir and ribavirin #liver15
Dr. Hezode: French compassionate use data for #sofosbuvir #daclatasvir in #HCV GT3 support 24 wks without RBV in cirrhosis #liver15
Dr. Leroy: ALLY-3+ #daclatasvir #sofosbuvir+RBV for 12 or 16 wks gets 90% SVR12 overall and 86% in cirrhotic HCV GT3 #Liver15 #LiverLeader
Current Wholesalers Acquisition Cost for IMPACT study combo of #simeprevir #sofosbuvir #daclatasvir? $223,860 #Liver15 #LiverLeader
"Kitchen sinking it" #simeprevir #sofosbuvir #daclatasvir for 12 weeks cures 100% #HCV GT1 Child Pugh A&B cirrhotics #Liver15 #LiverLeader
Dr. Herve: viral kinetics do not affect response to #sofosbuvir + #daclatasvir in recurrent #HCV after transplant #Liver15 #LiverLeader
Will 16 weeks of #daclatasvir #Sofosbuvir be enough for #HCV GT-3 with advanced fibrosis/cirrhosis? ALLY-3+ data at #liver15 #LiverLeader
# FDA approves #daclatasvir as new treatment for chronic #HCV genotype 3 #daklinza
www.fda.gov/NewsEvents/Newsroom/Pres...
#BMS news don't change status of #Sunvepra/#Daklinza combo approved in Japan for #HCV GT1b and #daclatasvir in EU as combo with other drugs
Asunaprevir (ASN)/Daclatasvir (DCV) combo gets FDA breakthrough drug designation for genotype 1b hepatitis c. #hcv #Daclatasvir
